
    
      60 patients with stageⅠ~ Ⅲ CRC, who had received surgery and kept their tumor tissue, will be
      randomly divided into group A (receive DC-CIK treatment, chemotherapy and radiotherapy) or
      group B (just receive chemotherapy and radiotherapy), and the randomize ratio will be 1:1.
      Patients in group A will receive 3 cycles of autologous tumor lysate pulsed DC-CIK cells
      treatment (every 4 weeks) and 4 cycles chemo-radiotherapy. Patients in group B will receive
      only 4 cycles chemo-radiotherapy.
    
  